RNAZ Stock Analysis: Buy, Sell, or Hold?
RNAZ - TransCode Therapeutics, Inc. Common Stock
$5.60
0.27 (5.07%)
▲
5d:
+10.02%
30d:
-17.51%
90d:
-42.77%
BUY
MODERATE Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When RNAZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RNAZ shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RNAZ shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RNAZ is currently trading at $5.60, which is considered fair relative to its 30-day fair value range of $5.18 to $6.68.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $3.82, while resistance sits at $6.30. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+87.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $3.82, while resistance sits at $6.30. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+87.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.18 -
$6.68
Company Quality Score
53/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 87.6% below Wall St target ($10.00)
Trading Range Analysis
30-Day Trading Range
$5.18 -
$6.68
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.82
Resistance Level
$6.30
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.66
Wall Street Target
$10.00
(+87.6%)
Share & Embed Analysis
Last updated: June 15, 2026 3:27 PM ET
Data refreshes hourly during market hours. Next update: 4:27 PM
Data refreshes hourly during market hours. Next update: 4:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 62 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 55 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 57 HOLD |
